Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021)
Janux Therapeutics (JANX) posted quarterly Preferred Stock Liabilities of $77.3 million for Q1 2021, up 257.69% quarter-over-quarter from $21.6 million in Q4 2020.
Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Janux Therapeutics (JANX) has reported Preferred Stock Liabilities for 2 consecutive years, with $77.3 million the latest figure, recorded in Q1 2021.
- In Q1 2021, Preferred Stock Liabilities changed N/A year-over-year to $77.3 million; the TTM figure through Mar 2021 stood at $77.3 million (changed N/A YoY), while the FY2020 annual figure was $21.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $77.3 million in Q1 2021 per JANX's latest filing, from $21.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $77.3 million in Q1 2021 and bottomed at $17.1 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 77.35 Mn |
| Dec 31, 2020 | 21.62 Mn |
| Sep 30, 2020 | 17.13 Mn |
| Jun 30, 2020 | 17.13 Mn |